Nuvilex, Inc. (OTCQB: NVLX), announced today that Goldman Research issued a report Tuesday, May 10, 2011, stating in the title, “Nuvilex, Inc., Natural Products Leader Is An Undiscovered Gem.” Goldman also clearly recognized Nuvilex as being currently “valued for its current portfolio only, so Investors get the rest of the Company for free” and “does not reflect the expected launch of new products or the value of the pre-clinical development portfolio.” The report rates Nuvilex a Speculative Buy adding “we believe that the shares could reach $0.50 by year end.” By the end of Tuesday when the report was issued, 2.41 Million shares had traded, stimulating one of the largest and most active days of trading since the management was changed in January. Dr. Robert Ryan, President and CEO commented, “We were extremely pleased to receive such a glowing report on Nuvilex and the recognition of both the importance of stabilization and expansion as we are striving to move the Company forward.”
